New Patent Issued in the United State (Patent No. 12460271)

C4U Corporation (“C4U”) is pleased to announce that the patent for the invention “METHOD FOR DETECTING SPECIFIC DNA IN A SAMPLE”, was issued in the United State on November 4, 2025 as Patent No. 12460721.   
This invention discovered that it is possible to detect the target DNA in the sample using, as an indication, a signal generated by the cleavage of the single-stranded probe DNA. By mixing a single-stranded probe DNA whose cleavage can be detected in a reaction system, CRISPR-Cas3 system and a sample, we could obtain fast and handy results of detection.
This invention has already been patented in Japan in 2021 as Patent No. 6940086, and this issue in the United States marks its first overseas issuance. Also, a grant eligibility notice has been issued in Singapore. 
C4U will continue to strengthen its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerate its application in a wide range of fields, including pharmaceutical field.

About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.　https://www.crispr4u.jp/en/